Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (252)	12/5/2002 10:39:30 AM
From: tuck	Respond to of 824

Just in case folks hadn't seen this . . . >>CHESHIRE, Conn., Dec. 5 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals (Nasdaq: ALXN - News) will conduct a conference call to review the results of its clinical trial of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) as presented at the American Society of Hematology Meeting. Monday, December 9, 2002 12:30 p.m. Eastern To participate in this call, dial: 719-457-2633 confirmation code: 508793 shortly before 12:30 p.m. Eastern To reserve a line, please call Rhonda Chiger at Rx Communications Group, LLC 917-322-2569. A replay of the call will be available from 3:30 p.m. Eastern through midnight Monday, December 16th, 2002. The replay number is 719-457-0820, confirmation code 508793. As previously announced, results of the Phase I pilot study of eculizumab in PNH patients will be presented at the 44th Annual American Society of Hematology (ASH) Meeting in Philadelphia on December 9th at 8:45am. The presentation will be made by Dr. Peter Hillmen, MB, ChB, PhD, Consultant Hematologist of The General Infirmary at Leeds, Leeds, United Kingdom. Alexion expects to issue a press release to coincide with the start of Dr. Hillmen's presentation.<< snip Cheers, Tuck

To: Icebrg who wrote (252)	4/21/2003 3:01:43 AM
From: Icebrg	Read Replies (1) \| Respond to of 824

Therapeutic potential of targeting the complement cascade in critical care medicine Deepak Bhole, PhD; Gregory L. Stahl, PhD Caring for the critical care patient involves many different areas of clinical expertise and serves a diverse patient population. Novel therapeutics for the critically ill must be approached with caution, because the underlying molecular mechanisms of the disease process for several commonly seen types of patients (i.e., sepsis, shock, ischemia/reperfusion) are not fully understood. A potentially new and advancing area of therapeutics that may hold promise for the critically ill is inhibition of the complement system. Various novel complement inhibitors are being developed and several are in clinical trials. The advancement of this novel area of therapeutics may one day aid the clinician by providing several different complement inhibitors/antagonists for controlling complement activation or its biologically active mediators. (Crit Care Med 2003; 31[Suppl.]:S97–S104) KEY WORD: cardiopulmonary bypass; sepsis; inflammation; C5a; mannose binding protein; C3a; C3; C1q; pexelizumab; TP-10 stahl.bwh.harvard.edu Comment: Interesting overview of the complement system. Article is available for download. Erik